Cargando…

Repurposing of drugs for triple negative breast cancer: an overview

Breast cancer (BC) is the most frequent cancer among women in the world and it remains a leading cause of cancer death in women globally. Among BCs, triple negative breast cancer (TNBC) is the most aggressive, and for its histochemical and molecular characteristics is also the one whose therapeutic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Spini, Andrea, Donnini, Sandra, Pantziarka, Pan, Crispino, Sergio, Ziche, Marina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cancer Intelligence 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7373643/ https://www.ncbi.nlm.nih.gov/pubmed/32728387 http://dx.doi.org/10.3332/ecancer.2020.1071

Ejemplares similares

Uncovering Knowledge Gaps in the Safety Profile of Antiangiogenic Drugs in Cancer Patients: Insights from Spontaneous Reporting Systems Studies
por: Ciccone, Valerio, et al.
Publicado: (2023)

Drug Repurposing for Triple-Negative Breast Cancer
por: Ávalos-Moreno, Marta, et al.
Publicado: (2020)

Does the oncology community have a rejection bias when it comes to repurposed drugs?
por: Gyawali, Bishal, et al.
Publicado: (2018)

Safety of Anti-Angiogenic Drugs in Pediatric Patients with Solid Tumors: A Systematic Review and Meta-Analysis
por: Spini, Andrea, et al.
Publicado: (2022)

Repurposing drugs in oncology (ReDO)—selective PDE5 inhibitors as anti-cancer agents
por: Pantziarka, Pan, et al.
Publicado: (2018)

Editorial: Drug Repurposing
por: Pantziarka, Pan, et al.
Publicado: (2019)

Real-World Utilization of Target- and Immunotherapies for Lung Cancer: A Scoping Review of Studies Based on Routinely Collected Electronic Healthcare Data
por: Spini, Andrea, et al.
Publicado: (2021)

ReDO_DB: the repurposing drugs in oncology database
por: Pantziarka, Pan, et al.
Publicado: (2018)

How to conjugate the stemness marker ALDH1A1 with tumor angiogenesis, progression, and drug resistance
por: Ciccone, Valerio, et al.
Publicado: (2020)

Targeting endothelial cell metabolism for cardio-protection from the toxicity of antitumor agents
por: Morbidelli, Lucia, et al.
Publicado: (2016)

Propranolol and breast cancer—a work in progress
por: Pantziarka, Pan, et al.
Publicado: (2018)

“Hard” Drug Repurposing for Precision Oncology: The Missing Link?
por: Pantziarka, Pan, et al.
Publicado: (2018)

A Database of Drug Repurposing Clinical Trials in Oncology
por: Pantziarka, Pan, et al.
Publicado: (2021)

The wisdom of crowds and the repurposing of artesunate as an anticancer drug
por: Augustin, Yolanda, et al.
Publicado: (2015)

Development and validation of a case-finding algorithm for the identification of non-small cell lung cancers in a region-wide Italian pathology registry
por: Spini, Andrea, et al.
Publicado: (2022)

Sex differences in the utilization of drugs for COVID‐19 treatment among elderly residents in a sample of Italian nursing homes
por: Spini, Andrea, et al.
Publicado: (2022)

Triple Negative Breast Cancer – An Overview
por: Aysola, Kartik, et al.
Publicado: (2013)

Endothelial Aldehyde Dehydrogenase 2 as a Target to Maintain Vascular Wellness and Function in Ageing
por: Nannelli, Ginevra, et al.
Publicado: (2020)

Repurposing Drugs in Oncology (ReDO)—mebendazole as an anti-cancer agent
por: Pantziarka, Pan, et al.
Publicado: (2014)

Repurposing Drugs in Oncology (ReDO)—itraconazole as an anti-cancer agent
por: Pantziarka, Pan, et al.
Publicado: (2015)

Repurposing Drugs in Oncology (ReDO)—diclofenac as an anti-cancer agent
por: Pantziarka, Pan, et al.
Publicado: (2016)

Repurposing drugs in oncology (ReDO)—cimetidine as an anti-cancer agent
por: Pantziarka, Pan, et al.
Publicado: (2014)

Repurposing Drugs in Oncology (ReDO)—nitroglycerin as an anti-cancer agent
por: Sukhatme, Vidula, et al.
Publicado: (2015)

The Repurposing Drugs in Oncology (ReDO) Project
por: Pantziarka, Pan, et al.
Publicado: (2014)

Repurposing Drugs in Oncology (ReDO)—Propranolol as an anti-cancer agent
por: Pantziarka, Pan, et al.
Publicado: (2016)

Validity of Italian administrative healthcare data in describing the real-world utilization of infusive antineoplastic drugs: the study case of rituximab use in patients treated at the University Hospital of Siena for onco-haematological indications
por: Bartolini, Claudia, et al.
Publicado: (2023)

Drug Repurposing by Tumor Tissue Editing
por: Lüke, Florian, et al.
Publicado: (2022)

Repurposing Drugs in Oncology (ReDO)—clarithromycin as an anti-cancer agent
por: Van Nuffel, An MT, et al.
Publicado: (2015)

New Insights Into Blood-Brain Barrier Maintenance: The Homeostatic Role of β-Amyloid Precursor Protein in Cerebral Vasculature
por: Ristori, Emma, et al.
Publicado: (2020)

Repurposing Infectious Diseases Vaccines Against Cancer
por: Vandeborne, Liese, et al.
Publicado: (2021)

An Overview of Circulating Cell-Free Nucleic Acids in Diagnosis and Prognosis of Triple-Negative Breast Cancer
por: Tierno, Domenico, et al.
Publicado: (2023)

Drug repurposing as a potential source of innovative therapies in cervical cancer
por: Capistrano I., Rica, et al.
Publicado: (2022)

Stemness marker ALDH1A1 promotes tumor angiogenesis via retinoic acid/HIF-1α/VEGF signalling in MCF-7 breast cancer cells
por: Ciccone, Valerio, et al.
Publicado: (2018)

Correction to: Stemness marker ALDH1A1 promotes tumor angiogenesis via retinoic acid/HIF-1α/VEGF signalling in MCF-7 breast cancer cells
por: Ciccone, Valerio, et al.
Publicado: (2019)

A Network-Based Data Integration Approach to Support Drug Repurposing and Multi-Target Therapies in Triple Negative Breast Cancer
por: Vitali, Francesca, et al.
Publicado: (2016)

Real word evidence on rituximab utilization: Combining administrative and hospital-pharmacy data
por: Roberto, Giuseppe, et al.
Publicado: (2020)

Investigational Drug Treatments for Triple-Negative Breast Cancer
por: Damaskos, Christos, et al.
Publicado: (2021)

Repurposing Drugs in Oncology (ReDO)—chloroquine and hydroxychloroquine as anti-cancer agents
por: Verbaanderd, Ciska, et al.
Publicado: (2017)

Informatics on Drug Repurposing for Breast Cancer
por: Zhou, Hui, et al.
Publicado: (2023)

Recent Advances in Drug Discovery for Triple-Negative Breast Cancer Treatment
por: Masci, Domiziana, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_s7df0pqfee3l9tbluu7d7nkiic